R&D channel feed

#ASH18: Re­gen­eron's bis­pe­cif­ic REGN1979 of­fers eye-catch­ing 80% CR rate in fol­lic­u­lar lym­phoma, spurring swift shift to piv­otal study

7 years ago

#ASH18: Ac­celeron and Cel­gene take cen­ter stage with a pair of PhI­I­Is for lus­pa­ter­cept they be­lieve will back up $2B-plus in rev­enue pro­jec­tions

7 years ago

As­traZeneca's res­pi­ra­to­ry team ac­knowl­edges its lat­est set­back, tri­al flops

7 years ago

Spot­light on drug pric­ing could be cat­a­lyst for change in US biosim­i­lar land­scape

7 years ago
Pharma

CRI study high­lights CT­LA-4's mar­quee role in PD-1/L1 com­bos — de­spite an in­creas­ing­ly trou­bled clin­i­cal pro­file

7 years ago

Lund­beck­'s Dun­sire has some­thing to cheer as Rex­ul­ti com­bo shows promise in PTSD

7 years ago

Sur­vey says: Brex­it blues hit bio­phar­ma as in­dus­try ex­ecs over­whelm­ing­ly turn thumbs down on the UK's fu­ture

7 years ago

Bay­er to cut in­ter­nal drug R&D work, ax­ing hun­dreds of re­searchers while look­ing to part­ners as it un­veils plan to slash 12,000 jobs

7 years ago

Low sales, high cost: Melin­ta slash­es HQ re­search staff as it strug­gles to grow an­tibi­otics rev­enue

7 years ago

The num­ber of I/O can­cer drugs in the clin­ic con­tin­ues to swell at an ex­plo­sive pace -- of­fer­ing new hope, fresh con­cerns

7 years ago

Af­ter get­ting beat up on its de­pres­sion drug pitch, a bat­tered Alk­er­mes piv­ots to schiz­o­phre­nia with a pos­i­tive PhI­II read­out — but skep­tics are ready to pounce

7 years ago

On a roll, Ver­tex racks up im­pres­sive PhI­II da­ta for VX-659 com­bos in cys­tic fi­bro­sis

7 years ago

Glob­al syn­di­cate backs $400M ge­nomics R&D play in Ire­land as WuXi NextCODE ex­tends its reach in­to Eu­rope

7 years ago
Financing
Pharma

Check­Mate-451: Bris­tol-My­ers’ Op­di­vo — plus Yer­voy — fails PhI­II com­bo lung can­cer study, the lat­est in a se­ries of set­backs

7 years ago

Déjà vu for Zaf­gen: Still fret­ting about lin­ger­ing car­dio con­cerns, FDA clamps a hold on lead obe­si­ty drug -- shares plunge

7 years ago

Vec­tura sinks af­ter PhI­II asth­ma tri­al ends in fail­ure, mark­ing an­oth­er set­back

7 years ago

Who are the best — and worst — among the ma­jor phar­mas at de­vel­op­ing drugs for the poor?

7 years ago

Stal­ler­genes Greer's dust mite al­ler­gy drug clears piv­otal study, edges clos­er to ap­proval

7 years ago

Pfiz­er, Mer­ck KGaA re­port their lat­est set­back with check­point con­tender Baven­cio

7 years ago

Aim­mune's peanut al­ler­gy treat­ment could 'change prac­tice' — with safe­ty chal­lenges and a price any­thing but peanuts

7 years ago

Un­de­terred by ex­ec ex­o­dus, Im­muno­core nabs $100M cash to co-de­vel­op pre­clin­i­cal as­set with Roche

7 years ago
Discovery

While con­tro­ver­sy over Brex­it reach­es full boil, a phar­ma trade group sees the up­side in a draft deal

7 years ago
Pharma

Sanofi teams with non-prof­it on a land­mark new drug for sleep­ing sick­ness

7 years ago
Discovery
Pharma

Eli Lil­ly part­ner Chi-Med sees shares tank as its new­ly ap­proved can­cer drug flunks PhI­II lung can­cer tri­al

7 years ago
First page Previous page 258259260261262263264 Next page Last page
A service from the Financial Times